Vyleesi and Trazodone Interaction: Safety, Risks, and Clinical Guidance

Vyleesi is the brand name for bremelanotide, a melanocortin-4 receptor (MC4R) agonist injected subcutaneously and FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Trazodone is a serotonin antagonist and reuptake inhibitor (SARI), taken orally, approved for major depressive disorder and commonly prescribed off-label for insomnia at lower doses. The two drugs are not chemically related and are not known to share a metabolic pathway.

No dedicated pharmacokinetic interaction study of bremelanotide combined with trazodone has been published, and the current FDA label for bremelanotide does not list trazodone among its labeled interactions. The concern is pharmacodynamic: bremelanotide can transiently raise blood pressure while trazodone's alpha-1 adrenergic blockade can lower it, and both drugs can cause sedation. Because of that overlap, most drug-interaction references treat the combination as moderate risk, meaning it is generally usable with monitoring and dose spacing rather than something that requires automatic avoidance. This page lays out what is established from the label and guidelines, what is pharmacologically plausible but unproven, and what a prescriber or pharmacist should verify before either drug is started.

Direct answer

Vyleesi and trazodone are not classified as a contraindicated combination. The interaction is pharmacodynamic rather than pharmacokinetic, driven by opposite and time-shifted effects on blood pressure plus additive sedation. A patient using both should expect guidance to separate dosing by several hours where possible, watch for dizziness or lightheadedness (especially when standing up), and check with the prescriber or pharmacist if either drug's dose changes.

How each drug works

Bremelanotide activates MC4R pathways in the central nervous system involved in sexual arousal. It is given as a 1.75 mg subcutaneous injection roughly 45 minutes before anticipated sexual activity, is not dosed daily, and the FDA label caps use at one injection per 24 hours with a maximum of 8 injections per month. Bremelanotide is cleared primarily through hydrolysis rather than major cytochrome P450 metabolism.

Trazodone blocks serotonin 5-HT2A receptors, weakly inhibits serotonin reuptake, and has meaningful alpha-1 adrenergic and histamine H1 antagonism, which is what produces its characteristic sedation and orthostatic blood pressure drop. It is metabolized mainly through CYP3A4. At antidepressant doses (commonly 150 to 400 mg/day) it is dosed daily; at the lower doses often used off-label for sleep (roughly 25 to 100 mg), the sedative effect is still clinically relevant even though total drug exposure is lower.

Because the two drugs are cleared through different pathways and neither is a strong inhibitor or inducer of the other's metabolism, the interaction risk here is about overlapping physiologic effects, not about one drug raising or lowering blood levels of the other. Any pharmacokinetic effect (for example, on drug absorption timing) should be treated as plausible but not established for this specific pair, since it has not been directly studied.

The blood pressure question: rise then fall

The FDA label for bremelanotide describes a transient increase in blood pressure following injection, with caution advised in patients who have cardiovascular risk factors or uncontrolled hypertension. Exact average blood pressure changes reported in the approval trials are cited in various secondary summaries, but the precise figures should be confirmed against the current label rather than assumed, since labeling and rounding conventions can shift between printings. What is consistently described is a peak effect in the hours following injection that resolves within about half a day.

Trazodone's alpha-1 blockade is a well-established cause of orthostatic hypotension, most pronounced in the first hour or two after an oral dose, and more likely in patients also taking antihypertensives or other vasodilating drugs.

The plausible sequence in a patient using both drugs is that bremelanotide's blood pressure rise is subsiding around the time trazodone's blood pressure-lowering effect is near its peak (if trazodone is dosed close in time), which could produce a larger net drop than either drug alone would cause. This mechanism is biologically reasonable given each drug's individually documented effect, but no published case series or trial has directly measured this combined blood pressure trajectory. That gap should be stated plainly rather than filled in with a number that has not been verified for this specific pairing.

Evidence-status interaction assessment

A prescriber or pharmacist reviewing this combination should verify, using a current interaction database and the current product labels, whether either label has been updated since this page was written, what the patient's baseline blood pressure and orthostatic history look like, and whether the patient is on any other blood pressure-lowering or sedating medication.

Sedation overlap

Bremelanotide's label lists fatigue as a recognized, less common adverse effect (nausea is the most frequently reported effect overall). Trazodone is well known clinically as one of the more sedating antidepressants, with drowsiness that typically peaks within the first hour or two after an oral dose.

When both drugs are active in the body at the same time, the expected effect is additive drowsiness, slowed reaction time, and reduced coordination, not the kind of severe respiratory or CNS depression seen with combinations like opioids and benzodiazepines. The practical risks are impaired alertness and an increased chance of a fall or a dizzy spell, particularly if the patient stands up quickly.

Because bremelanotide is used as needed before sexual activity and trazodone for insomnia is typically taken at bedtime, a patient could reasonably use both within the same evening. Spacing the two doses further apart, where the treatment plan allows it, reduces the window in which both effects are near peak intensity at once.

What interaction-checking databases say

Commercial and clinical interaction databases (such as those used by pharmacists and electronic health record systems) generally classify pharmacodynamic overlaps like this one as moderate severity, meaning monitoring is advised rather than automatic avoidance. Exact wording and severity tiers vary by vendor and are updated periodically, so a specific rating quoted today should be reconfirmed against the current version of whichever database a clinician or pharmacy is using rather than treated as fixed.

The FDA label for bremelanotide lists one drug interaction at a contraindication level: concurrent use with oral naltrexone, because bremelanotide reduces naltrexone absorption and can lower naltrexone's effectiveness. Trazodone is not named in the bremelanotide label. Absence from the label does not mean no interaction exists; it means the combination has not been the subject of a dedicated interaction study, and the underlying concern here is inferred from each drug's separately known pharmacology rather than from direct testing of the pair.

No published case reports describing an adverse event from the bremelanotide-trazodone combination specifically were identified for this article. Given how recently bremelanotide reached the market relative to trazodone's long history of use, the absence of reports likely reflects limited combined exposure and reporting rather than confirmed safety, and this should be treated as an evidence gap rather than reassurance.

Practical timing and monitoring

Separating the two drugs by several hours, where a patient's regimen allows it, reduces the window during which bremelanotide's blood pressure rise and trazodone's blood pressure drop and sedation are both near peak. For a patient taking trazodone at bedtime for insomnia, using bremelanotide earlier in the evening (rather than immediately before bed) gives bremelanotide's cardiovascular effect more time to resolve before trazodone's peak effect arrives.

For a patient on standing daily trazodone for depression, the picture is different: trazodone is present at a steady level throughout the day, so there is no dosing window to avoid. In that case, the practical focus shifts to checking blood pressure and orthostatic symptoms after starting or restarting bremelanotide, rather than trying to time doses apart.

Reasonable, non-individualized steps to discuss with a prescriber include:

• Checking a baseline blood pressure before the first time bremelanotide and trazodone are used together.
• Not exceeding the labeled bremelanotide frequency (one injection per 24 hours, up to 8 per month).
• Spacing bremelanotide and as-needed or bedtime trazodone doses apart by several hours when the treatment plan allows.
• Rising slowly from sitting or lying positions, especially in the hours after a bremelanotide injection on a day trazodone is also taken.
• Avoiding alcohol on days both drugs are used, since alcohol independently lowers blood pressure and adds sedation.
• Reporting new or worsening dizziness, lightheadedness, or fainting to the prescriber promptly rather than waiting for a routine visit.

This is general information, not an individualized dosing or monitoring schedule. The right interval and monitoring plan depend on the patient's baseline blood pressure, other medications, and cardiovascular history, and should be set by the prescriber.

Who should be more cautious

Patients with uncontrolled hypertension or known cardiovascular disease are already flagged for caution on the bremelanotide label independent of any other medication; adding a drug with a known orthostatic hypotension liability is a reasonable additional reason for closer monitoring in this group.

Patients with a personal history of syncope or vasovagal episodes may be more susceptible to a combined blood pressure swing and should discuss the combination with a prescriber before starting.

Patients on trazodone alongside other serotonergic medications (SSRIs, SNRIs, buspirone, triptans) carry a separate, better-established concern for serotonin syndrome that relates to the serotonergic combination itself, not to bremelanotide, since bremelanotide has no known serotonergic activity.

Bremelanotide's other labeled interactions

Beyond trazodone, the bremelanotide label describes reduced absorption of oral naltrexone when the two are co-administered, which is the basis for the label's recommendation against concurrent use. The label also describes an effect on the absorption of oral indomethacin taken close in time to bremelanotide, attributed to bremelanotide's effect on gastric motility, and advises caution with concomitant oral medications that have a narrow therapeutic index. Exact percentage changes reported for these interactions should be checked against the current label rather than assumed, since this article is not attaching an unverifiable specific number to either effect.

If bremelanotide slows gastric motility broadly, it is plausible that it could also delay absorption of an oral trazodone dose taken close in time, which would shift trazodone's peak effect later rather than earlier. This is a mechanistic possibility, not a documented finding for this pair, and is another reason to favor separating doses by a clear margin rather than taking them at the same time.

Evidence boundary

Established: bremelanotide transiently raises blood pressure per its FDA label; trazodone causes orthostatic hypotension and sedation as a known class and drug-specific effect; bremelanotide is contraindicated with oral naltrexone.

Plausible but unproven: that combining bremelanotide and trazodone produces a clinically larger blood pressure swing or more pronounced sedation than either drug's individually documented effect would predict; that bremelanotide meaningfully delays trazodone absorption.

Not established: any specific numeric estimate of combined blood pressure change or sedation severity for this exact drug pair; whether real-world adverse events from this combination are rare because they do not occur, or because they are underreported.

When to seek urgent care

Fainting, chest pain, severe or persistent dizziness, confusion, or a fall with injury after taking either drug warrants urgent medical evaluation rather than waiting to discuss it at a routine follow-up. Sustained blood pressure readings well outside a patient's normal range, in either direction, should also prompt a call to the prescriber the same day.